Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2009. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
There are no material changes to financial performance reported. The only reported activity is an increase in share interests for specific executives following the re-investment of dividends paid on April 9, 2009.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a procedural disclosure regarding share ownership.
Important Facts for Investors
- Directors and managers increased their shareholdings via dividend re-investment on April 17, 2009.
- The purchase price was £10.33 per share.
- Specific share increases included: Mr A P Witty (171 shares), Dr M M Slaoui (378 shares), Mr M Dunoyer (183 shares), Dr D Pulman (279 shares), and Ms C Thomas (71 shares).
- The notification was issued by the Company Secretary on June 2, 2009.